Table 1.
Patient characteristics
| N = 31 | % | |
|---|---|---|
| Age, years | ||
| Median (range) | 69 (38–82) | |
| ≥ 65 years | 18 | 58 |
| Sex | ||
| Male | 13 | 39 |
| ECOG PS | ||
| 0 | 31 | 100 |
| 1 | 0 | 0 |
| Primary location | ||
| Left | 24 | 77 |
| Right | 7 | 23 |
| Synchronous presentation | ||
| – | 17 | 54 |
| ≥ 18 months from diagnosis of metastatic disease to investigational treatment | ||
| – | 17 | 55 |
| Number of metastatic sites | ||
| ≤ 3 | 30 | 97 |
| > 3 | 1 | 3 |
| Liver metastases | ||
| – | 21 | 64 |
| Peritoneal carcinomatosis | ||
| – | 8 | 24 |
| Lung metastases | ||
| – | 16 | 55 |
| Previous lines of treatment | ||
| Median (range) | 2 (0–5) | |
| ≤ 2 | 23 | 74 |
| > 2 | 8 | 26 |
| Previous anti-angiogenic treatment | ||
| – | 26 | 84 |
| RAS status | ||
| Wild-type | 20 | 65 |
| Mutant | 11 | 35 |
| BRAF status | ||
| Wild-type | 30 | 95 |
| Mutant | 1 | 5 |
| MMR status | ||
| Unknown | 13 | 42 |
| MSI-H | 3 | 10 |
| MSS | 15 | 48 |
| Primary tumor resection | ||
| – | 25 | 71 |
| Surgery/locoregional treatment for metastatic disease | ||
| – | 9 | 29 |
ECOG PS Eastern Cooperative Oncology Group performance status, MMR mismatch repair, MSI-H microsatellite instability-high, MSS microsatellite stable